References
- 1. Abdel-Magid A. F. (2015). Inhibitors of the Antiapoptotic Myeloid Cell Leukemia-1 (Mcl-1) May Provide Effective Treatment for Cancer. ACS Medical Chemistry Letter, 6: 1171–1173. dx.doi.org/10.1021/acsmedchemlett.5b0043810.1021/acsmedchemlett.5b00438
- 2. AlBakr R. B, Khojah O. T. (2014). Incidence Trend of the Leukemia Reported Cases in the Kingdom of Saudi Arabia, Observational Descriptive Statistic from Saudi Cancer Registry. International Journal Biomedical Research, 5(8).
- 3. Anderson M. A, Huang D, Robertsa A. 2014. Targeting BCL2 for the Treatment of Lymphoid Malignancies. Seminar of Hematolology, 51(3), 219–227.
- 4. Marshall K. D & Baines C. P. 2014. Necroptosis: Is there a role for mitochondria? Frontier of Physiology, 5, 323.
- 5. Asif N, Hassan K. 2013. Acute Myeloid Leukemia amongst Adults. Journal of Islamabad Medical & Dentistry College (JIMDC), 2(4), 58-63.
- 6. Zhao H, Jaffer T, Eguchi S, Wang Z, Linkermann A, Ma D. (2015). Role of necroptosis in the pathogenesis of solid organ injury. Cell death and disease, 6, 1-10.
- 7. Gozuacik D, Kimchi A. (2007). Autophagy and Cell Death. Current topics in developmental biology, 78, 217-245. https://doi.org/10.1016/S0070-2153(06)78006-110.1016/S0070-2153(06)78006-1
- 8. Martin S. J, Henry C. M, Cullen S.P. (2012). A perspective on mammalian caspases as positive and negative regulators of inflammation. Molecular, 46(4), 387–397. doi: 10.1016/j.molcel.2012.04.026.22633487
- 9. Mohana-Kumaran N, Hill D. S, Allen J. D, Haass N. K. (2014). Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. Pigment Cell Melanoma Research, 4, 525-39. doi:10.1111/pcmr. 12242. Epub 2014.10.1111/pcmr.12242.Epub2014
- 10. Hajji N. Joseph B. (2010). Epigenetic regulation of cell life and death decisions and deregulation in cancer. Essays in Biochemistry, 48, 121-146.
- 11. Hockenbery D. M. (1994). bcl-2 in cancer, development and apoptosis. Journal of Cell Science, Supplement, 18, 51–55.
- 12. Yip K. W, Reed J. C. (2008). Bcl-2 family proteins and cancer. Oncogene, 27(50), 6398–6406. https://doi.org/10.1038/onc.2008.30710.1038/onc.2008.307
- 13. Frenzel, A., Grespi, F., Chmelewskij, W. & Villunger. A. (2009). Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis. 14(4); 584–596. doi:10.1007/s10495-008-0300-z.10.1007/s10495-008-0300-z
- 14. Kelly P, Strasser A. (2011). The role of Bcl-2 and its prosurvival relatives in tumourigenesis and cancer therapy. Cell Death and Different, 18(10), 1414–1424. https://doi.org/10.1038/cdd.2011.17
- 15. Susan F. L, Brad C. T. (2005). Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infection and immunity, 73(4), 1907-16.
- 16. Doerflinger M, Glab J. A, Puthalakath H. (2015). BH3- only proteins: a 20-year stock-take. FEBS Journal, 282,1006–1016. doi:10.1111/febs.13190
- 17. Dewson, G, Kluck R. M. (2009). Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. Journal of Cell Science, 122, 2801-8.
- 18. Ghatage D D, Gosavi S R, Ganvir S. M, Hazarey V. K. (2012). Apoptosis: Molecular mechanism. Journal Orofacial Science, 4 (2).
- 19. Barak Y, Juven T, Haffner R. (1993). mdm2 expression is induced by wild type p53 activity. EMBO Journal, 12, 461–468.
- 20. Belizário J, Cordeiro L. V, Enns S. (2015). Necroptotic Cell Death Signaling and Execution Pathway: Lessons from Knockout Mice. Hindawi Publishing Corporation Mediators of Inflammation, 15.
- 21. Bensi L, Longo R, Vecchi A, Messora C, Garagnani L, Bernardi M. S, Tamassia G, Sacchi S. (1995). BCL-2 Oncoprotein Expression in Acute Myeloid Leukemia. Haematology, 80, 98-102.
- 22. Billard C. (2015). Apoptosis as a Therapeutic Target in Chronic Lymphocytic Leukemia. Lymphocytitc and Chonic Lymphocytic Leukemia, 5, 11–15. doi:10.4137/LCLL.S13718.10.4137/LCLL.S13718
- 23. Blau O. (2015). Gene Mutations in Acute Myeloid Leukemia- Incidence, Prognostic Influence, and Association with Other Molecular Markers. INTECH, 75-100.
- 24. Blatt N. B, Glick G. D. (2001). Signaling pathways and effector mechanisms pre-programmed cell death. Bioorganic and Medical Chemistry, 9(6), 1371-84.
- 25. Fisher A. (1937). The theory of the developmental physiology of malignant tumor. The American journal of cancer, 31(10).
- 26. Breckenridge D. G, Germain M, Mathai J. P, Nguyen M, Shore G. C. (2003) Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene, 22, 8608–8618. doi:10.1038/sj.onc.120710810.1038/sj.onc.1207108
- 27. Bruin E. C, Medema J. P. (2008). Apoptosis and nonapoptotic deaths in cancer development and treatment response. Cancer Treatment Reviews, 34(8), 737-749. doi: http://dx.doi.org/10.1016/j.ctrv.2008.07.001
- 28. Brunelle J. K, Letai A. (2009). Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Science, 122, 437-441.
- 29. Chaabane W, User S. D, El-Gazzah M, Jaksik R, Sajjadi E, Rzeszowska-Wolny J, Łos M. J. (2013). Autophagy, Apoptosis, Mitoptosis and Necrosis: Interdependence Between Those Pathways and Effects on Cancer. Archive of Immunology Therapy and Experimental, 61, 43–58, (2013). DOI 10.1007/s00005-012-0205-y10.1007/s00005-012-0205-y
- 30. Chipuk J. E. (2015). BCL-2 proteins: melanoma lives on the edge. Oncoscience, 34(7), 857-67.
- 31. Chonghaile T. N, Letai A. (2009). Mimicking the BH3 domain to kill cancer cells. Oncogene, 27, 149–157. doi:10.1038/onc.2009.5210.1038/onc.2009.52
- 32. Thorburn A. (2008). Apoptosis and autophagy: regulatory connections between two supposedly different processes. Apoptosis, 13(1), 1-9. Doi: 10.1007/s10495-007-0154-910.1007/s10495-007-0154-9
- 33. Kelly P, Strasser A. (2011). The role of Bcl-2 and its prosurvival relatives in tumourigenesis and cancer therapy. Cell Death and Differentiation, 18(10), 1414–1424. https://doi.org/10.1038/cdd.2011.17
- 34. Palai T. K, Mishra S. R. (2015). Caspases: An apoptosis mediator. Journal of Advanced Veerinary and Animal Research, 2(1), 18-22. doi: 10.5455/javar.2015.b5210.5455/javar.2015.b52
- 35. Shimizu S, Yoshida T, Tsujioka M, Arakawa S. (2014). Autophagic Cell Death and Cancer. International Journal of Molecular Science, 15, 3145-3153. doi:10.3390/ijms1502314510.3390/ijms15023145
- 36. Siddiqui W. A, Ahad A, Ahsan H. (2015). The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update. Archives of Toxicology, 89, 289-317.
- 37. Singh L, Pushker N, Saini N, Sen S, Sharma A, Bakhshi S, Chawla B, Kashyap S. (2015). Expression of proapoptotic Bax and anti-apoptotic Bcl-2 proteins in human retinoblastoma. Clinical Experimental Ophthopedic, 43, 259–267. doi: 10.1111/ceo.123910.1111/ceo.1239
- 38. Su Z, Yang Z, Xu Y, Chen Y, Qiang Y. Q. (2015). Apoptosis, autophagy, necroptosis, and cancer metastasis. Molecular Cancer, 14(48). Doi:10.1186/s12943-015-0321-510.1186/s12943-015-0321-5
- 39. Guicciardi M. E, Gores G. J. (2009). Life and death by death receptors. FASEBJ, 23(6), 1625-37. doi: 10.1096/fj.08-111005.10.1096/fj.08-111005
- 40. Marsden V. S, Ekert P. G, Delft M. V, Vaux D. L, Adams J. M, Strasser A. (2004). Bcl-2–regulated apoptosis and cytochrome c release can occur independently of both caspase-2 and caspase- 9. The Journal of Cell Biology, 165(6),775–780. http://www.jcb.org/cgi/doi/10.1083/jcb.20031203010.1083/jcb.200312030
- 41. Mason K, Vandenberga C. J, Scotta C. L, Wei A. H, Corya S, Huanga D. (2008). In vivo ef cacy of the Bcl- 2 antagonist ABT-737 against aggressive Myc-driven lymphomas. The Proceedings of the National Academy of Sciences, 105, 17961-17966.
- 42. Mérino D, Khaw S. L, Glaser S. P, Anderson D. J, Belmont L. D, Wong C. (2012). Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263 in lymphoid and leukemic cells. Blood, 119, 5807-5816.
- 43. Mehdipour P, Santoro F, Minucci S.(2015). Epigenetic alterations in acute myeloid leukemias. FEBS Journal, 282, 1786–1800. doi:10.1111/febs.1314210.1111/febs.13142
- 44. Momand J, Zambetti G. P, Olson D. C. (1991). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237–1245.
- 45. Kang M. H, Reynolds C. P. (2009). Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy. Clinical Cancer Research, 15(4). doi:10.1158/1078-0432.CCR-08-014410.1158/1078-0432.CCR-08-0144
- 46. Koff J. L, Ramachandiran S, Bernal-Mizrachi L. (2015). A Time to Kill: Targeting Apoptosis in Cancer. International Journal Molecular Science, 16, 2942-2955. doi:10.3390/ijms1602294210.3390/ijms16022942
- 47. Kontny U, Lissat A. (2015). Apoptosis and drug resistance in malignant bone tumors. Primary bone tumours. Doi: 10.1016/B978-0-12-416721-6.00036-410.1016/B978-0-12-416721-6.00036-4
- 48. Lavrik I. N. (2014). Systems biology of death receptor networks: live and let die. Cell Death and Disease, 5. doi:10.1038/cddis.2014.16010.1038/cddis.2014.160
- 49. Leber B, Lin J, Andrews D. W. (2010). Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene, 29, 5221-30.10.1038/onc.2010.283
- 50. Letai A, Sorcinelli M. D, Beard C, Korsmeyer S. J. (2002). Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell, 6, 241–9.
- 51. Le´veille F, Papadia S, Fricker M, Bell K. F. S, Soriano F. X, Martel M, Puddifoot C, Habel M, Wyllie D. J, Ikonomidou C, Tolkovsky A. M, Hardingham G. E. (2010). Suppression of the Intrinsic Apoptosis Pathway by Synaptic Activity. The Journal of Neurology, 30(7), 2623–2635.
- 52. Liu B, Bhatt D, Oltvai Z. N, Greenberger J. S, Bahar I. (2014). Significance of p53 dynamics in regulating apoptosis in response to ionizing radiation, and polypharmacological strategies. Scientific Reports, 4, 6245. Doi: 10.1038/srep0624510.1038/srep06245
- 53. Li M. X, Dewson G. (2015). Mitochondria and apoptosis: emerging concepts. F1000Prime Reports, 7(42). doi:10.12703/P7-42.10.12703/P7-42
- 54. Abramowitz J, Neuman T, Perlman R, Ben-Yehuda D. (2017). Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia. BMC Medical Genomics, 10(1),18. https://doi.org/10.1186/s12920-017-0249-210.1186/s12920-017-0249-2
- 55. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian S. V, Hainaut P, Olivier M. (2007). Impact of Mutant p53 Functional Properties on TP53 Mutation Patterns and Tumor Phenotype: Lessons from Recent Developments in the IARC TP53 Database. Human mutation, 28(6), 622-629.
- 56. Llambi F, Moldoveanu T, Tait Stephen W. G, Bouchier- Hayes L, Temirov J, McCormick L. L, Dillon C. P, Green D. R. (2011). A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Molecular Cell, 44, 517-31.10.1016/j.molcel.2011.10.001
- 57. Fulda S, Debatin K. M. (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene, 25(34), 4798-811.
- 58. Löwenberg B, Rowe J. M. (2015). Introduction to the review series on advances in acute myeloid leukemia (AML). Blood, 127(1). doi:10.1182/blood-2015-10-6626810.1182/blood-2015-10-66268
- 59. Mongiat M, Ligresti G, Marastoni S, Lorenzon E, Doliana R, Alfonso C. Regulation of the Extrinsic Apoptotic Pathway by the Extracellular Matrix Glycoprotein EMILIN2. (2007). Molecular Cell Biology, 27(20), 7176–7187. doi:10.1128/MCB.00696-0710.1128/MCB.00696-07
- 60. Moore V. D. G, Letai A. (2012). BH3 profiling – measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Letter, 332(2), 202–205. doi:10.1016/j.canlet.2011.12.021.10.1016/j.canlet.2011.12.021
- 61. Moore D. G. V, Brown J. R, Certo M. (2007). Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. Journal of Clinical Investiment, 117, 112–21.
- 62. Naseri H. M, Mahdavi M, Davoodi J, Tackallou S. H, Goudarzvand M, Neishabouri S. H. (2015). Up regulation of Bax and down regulation of Bcl2 during 3-NC mediated apoptosis in human cancer cells. Cancer Cell International, 15(55). Doi: 10.1186/s12935-015-0204-210.1186/s12935-015-0204-2
- 63. Ng S. Y, Davids M. S. (2014). Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clinical Advanced Hematology Oncology, 12(4), 224-9.
- 64. Noguchi M, Hirata N, Edamura T, Ishigaki S, Suizu F. (2015). Intersection of Apoptosis and Autophagy Cell Death Pathways. Austin Journal of Molecular & Cell Biology, 2(1), 1004.
- 65. Oltersdorf T, Steven W, Elmore S. W, Shoemaker A. R, Armstrong R. C, Augeri D. J, Belli B. A. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 435, 677-681.
- 67. Gibson L, Holmgreen S. P, Huang D. C, Bernard O, Copeland N. G, Jenkins N. A, Sutherland G. R, Baker E, Adams J. M, Cory S. (1996). Bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncology, 13(4), 665-75.
- 68. Zhong Q, Gao W, Du F, Wang X. (2005). Mule/ARFBP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquiti-nation of Mcl-1 and regulates apoptosis. Cell, 121, 1085–1095.
- 69. Czabotar P. E, Lee E. F, Delft M. F, Day C. L, Smith B. J, Huang D. C. S, Fairlie W. D, Hinds M. G, Colman P.M. (2007). Structural insights into the degradation of Mcl-1 induced by BH3 domain. Proceedings of the National Academy of Sciences, 104 (15) 6217-6222. DOI:10.1073/pnas.070129710410.1073/pnas.0701297104
- 70. Huang D. C. S, Strasser A. (2000). BH3-Only Proteins— Essential Initiators of Apoptotic Cell Death. Cell, 103, 839–842.
- 71. Shamas-Din A, Kale J, Leber B, Andrews D. W. (2013). Mechanisms of Action of Bcl-2 Family Proteins. Cold Spring Harbor Perspective in Biology. doi: 10.1101/cshperspect. a00871410.1101/cshperspect.a008714
- 72. Belka C, Budach W. (2002). Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology. International journal of radiation Biology, 78(8), 643-658. Doi: 10.1080/0955300021013768 0
- 73. Bouillet P, Metcalf D, Huang D. C, Tarlinton D. M, Kay T. W, Kontgen F, Adams J. M, Strasser A. (1999). Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science, 286, 1735–1738.
- 74. Polcic P, Jaká P, Mentel M. (2015). Yeast as a tool for studying proteins of the Bcl-2 family. Microbiology Cell, 2(3), 74-87. doi: 10.15698/mic2015.03.19310.15698/mic2015.03.193
- 75. Sáez G. A. J. (2012). The secrets of the Bcl-2 family. Cell Death Differentiation, 11, 1733-40. doi: 10.1038/cdd.2012.105.10.1038/cdd.2012.105
- 76. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli K. J, Debatin K. M, Krammer P. H, Peter M. E. (1998). Two CD95 (APO-1/Fas) signaling pathways. The EMBO Journal, 17(6), 1675–1687.10.1093/emboj/17.6.1675
- 77. Schnerch D, Yalcintepe J, Schmidts A, Becker H, Follo M, Engelhardt M, Wäsch R. (2012). Cell cycle control in acute myeloid leukemia. American Journal of Cancer Research, 2(5), 508-528.
- 78. Scandura J. M, Boccuni P, Cammenga J, Nimer S. D. (2002). Transcription factor fusions in acute leukemia: variations on a theme. Oncogene, 21, 3422-3444. Doi: 10.1038/sj/onc/120531510.1038/sj/onc/1205315
- 79. Shimizu S, Yoshida T, Tsujioka M, Arakawa S. (2014). Autophagic Cell Death and Cancer. International Journal of Molecular Science, 15, 3145-3153. doi:10.3390/ijms1502314510.3390/ijms15023145
- 80. Smaili S. S, Hsu Y. T, Carvalho A. C. P, Rosenstock T. R, Sharpe J. C, Youle, R. J. (2003). Mitochondria, calcium and pro-apoptotic proteins as mediators in cell death signaling. Brazilian Journal of Medical Biology Research. 36(2), 183-190.
- 81. Strasser A. (2005). The role of BH3-only proteins in the immune system. Nature Reviews Immunology, 5, 189-200.doi:10.1038/nri156810.1038/nri1568
- 82. Sun Z, Cheng Z, Taylor C. A, McConkey B, Thompson J. E. (2010). Apoptosis Induction by eIF5A1 Involves Activation of the Intrinsic Mitochondrial Pathway. Journal of Cell Physiology, 223, 798–809. Doi: 10.1002/jcp.2210010.1002/jcp.22100
- 83. Tian K.Y, Liu X. J, Xu J.D, Deng L. J, Wang G. (2015). Propofol inhibits burn injury-induced hyperpermeability through an apoptotic signal pathway in microvascular endothelial cells. Brazilian Journal of Medical Biology Research, 48(5), 401-407. http://dx.doi.org/10.1590/1414-431X2014410710.1590/1414-431X20144107
- 84. Trump B. F, Berezesky I. K, Chang, S. H, Phelps P. C. (1997). The Pathways of Cell Death: Oncosis, Apoptosis, and Necrosis. Toxicologic Pathology, 25(1), 82-8. Doi: 10.1177/019262339702500116
- 85. Tiwari M, Sharma L. K, Saxena A. K, Godbole M. M. (2015). Interaction Between Mitochondria and Caspases: Apoptotic and Non-Apoptotic Roles. Cell Biology, 3(2), 22-30. doi: 10.11648/j.cb.s.2015030201.1410.11648/j.cb.s.2015030201.14
- 86. Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. (2012). The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. Hindawi Public Corporation Advanced Hematology, doi:10.1155/2012/524308.10.1155/2012/524308
- 87. Vela L, Gonzalo O, Naval J, Marzo I. (2013). Revealed by fluorescence complementation. Journal of Biological Chemistry, doi:10.1074/jbc.M112.42220410.1074/jbc.M112.422204
- 88. Verbrugge I, Johnstone R. W, Smyth M. J. (2010). Snap- Shot: Extrinsic Apoptosis Pathways. Cell, 143(7), 1192. DOI 10.1016/j.cell.2010.12.00410.1016/j.cell.2010.12.004
- 89. Vo T. T, Ryan J, Carrasco R, Neuberg D, Rossi D. J, Stone R. M, Letai A. (2012). Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell, 151(2), 344-355.
- 90. El-Shakankiry N. H, El-Sayed G. M, El-Maghraby S, Moneer M. M. (2009). Bcl-2 protein expression in egyptian acute myeloid leukemia. Journal of Egypt Natural Cancer Institute, 21(1), 71–6.
- 91. Shi Y. (2002). Mechanisms of caspase activation and inhibition during apoptosis. Molecular Cell. https://doi.org/10.1016/S1097-2765(02)00482-310.1016/S1097-2765(02)00482-3
- 92. Wang R. A, Li Z. S, Yan Q. Q, Bian X. W, Ding Y. Q, Xiang D. X, Sun B. C, Yun-Tian S. Y. T, Xiang-Hong Zhang X. H. (2014). Resistance to apoptosis should not be taken as a hallmark of cancer. Chinese Journal of Cancer, 33(2).
- 93. Wei A. Teh T. C. (2012). Primed for the kill: occupying Bcl-2 to target death in acute myeloid leukaemia. Bio- Discovery, 6(1). doi:10.7750/BioDiscovery.2012.610.7750/BioDiscovery.2012.6
- 94. Weyhenmeyer B, Murphy A. C, Prehn J. H. M, Murphy B. M. (2012). Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer. Experimental Oncology, 34, 192–199.23070004
- 95. Woess C, Tuzlak S, Labi V, Drach M, Bertele D, Schneider P, Villunger A. (2015). Combined loss of the BH3- only proteins Bim and Bmf restores B-cell development and function in TACI-Ig transgenic mice. Cell Death Differentiation, 22, 1477–1488. doi: 10.1038/cdd.2015.810.1038/cdd.2015.8
- 96. Wu M, Ding H. F, Fisher D. E. Apoptosis: Molecular Mechanisms. Encyclopedia of Life Science 2001.10.1023/A:1011342220621
- 97. Yip K. W, Reed J. C. (2008). Bcl-2 family proteins and cancer. Oncology, 27, 6398–6406.
- 98. Yohe S. (2015). Molecular Genetic Markers in Acute Myeloid Leukemia. Journal of Clinical Medicine, 4, 460-478 (2015). doi:10.3390/jcm403046010.3390/jcm4030460
- 99. Youle R. J, Strasser A. (2005). The BCL-2 protein family: op- posing activities that mediate cell death. Nature Reviews of Molecular and Cell Biology, 9, 47–59.
- 100. Perez-Stable C, Parrondo R, De Las Pozas A, Reiner T. (2013). ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic- mediated apoptosis in human prostate cancer cells. Biochemistry, biophysics and molecular biology, https://doi.org/10.7717/peerj.14410.7717/peerj.144
- 101. Zhao G, Zhu Y, Eno C. O, Liu Y, DeLeeuw L, Joseph A, Burlison J. A, Chaires J. B, Trent J. O, Li C. (2014). Activation of the Proapoptotic Bcl-2 Protein Bax by a Small Molecule Induces Tumor Cell Apoptosis. Molecular Cell Biology, 34(7), 1198–1207. doi:10.1128/MCB.00996-1310.1128/MCB.00996-13
- 102. Zong W. X, Lindsten T, Ross A. J, MacGregor G. R, Thompson C. B. (2001). BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Gene & Development, 15, 1481–1486.10.1101/gad.897601